Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.

In particular, the substantial MFI level upregulation of IFN-γ, a known mediator with a direct impact on tumor reduction, observed in the combination group was highly significant ( P < 0.05) whereas it was not significantly increased when compared with the denfivontinib group ( Fig. 2C and D ).

also in 132,142 other papers